Not recruiting
Endometrial cancer+1
Not recruitingStudy of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy
Registered drugNo placebo
Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy
Registered drugNo placebo
- Disease:Endometrial cancerCervix carcinoma
- Substances:CarboplatinPaclitaxel+2
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
